In the final part of his Pharma Commerce video interview, Dan Walles, VP & GM, traceability and compliance solutions, ...

The agreement includes exemptions for UK-produced drugs and medical devices from Section 232 tariffs, but mandates a ...

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, ...

In legacy systems, it takes 10-14 days on average to move a prescription from signature to first fill – and half the time, the patient gives up. DTP compresses that window to days or hours by ...

CMS announced a 44% net savings on 15 high-cost drugs under Medicare, effective January 2027, as part of the Inflation ...

As the deadline draws near, the organizations that will succeed under DSCSA are those that understand compliance is not a ...

In today’s Pharma Pulse, the federal government prepares to unveil newly negotiated Medicare prices for 15 high-cost drugs, while Novartis receives FDA approval for Itvisma, a one-time gene therapy ...

Medicare will announce negotiated prices for 15 high-cost drugs, impacting over 67 million beneficiaries. The Inflation ...

Although CNPVs are widely viewed as a valuable opportunity, the criteria for selection remain somewhat opaque. One of the program’s stated goals is to bolster domestic drug production, particularly ...

A new Pharma Pulse briefing unpacks declining RSV vaccine durability in older adults, AstraZeneca’s $2 billion expansion of its US biologics manufacturing footprint, and the stock-shaking Phase III ...

As the deadline draws near, the organizations that will succeed under DSCSA are those that understand compliance is not a checkbox, but rather, a fully integrated operational discipline. He also ...